Last reviewed · How we verify
NCT05988645
Performance and Safety of MiWEndo-assisted Colonoscopy (MiWEndo II)
NA trial testing MiWEndo System in Colorectal Cancer in 50 participants. Currently enrolling.
29 December 2025
Quick facts
| Lead sponsor | MiWEndo Solutions S.L. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 50 |
| Start date | 1 August 2023 |
| Primary completion | 29 December 2025 |
| Estimated completion | 29 December 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- MiWEndo System
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Colorectal Polyp — all drugs for Colorectal Polyp →
- Colorectal Adenoma — all drugs for Colorectal Adenoma →
- Colorectal Adenomatous Polyp — all drugs for Colorectal Adenomatous Polyp →
Sponsor
MiWEndo Solutions S.L.
Who can join
18 and older, any sex, with Colorectal Cancer or Colorectal Polyp. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study involves the planned use of a new microwave-based device during colonoscopy procedures in 50 patients to assess the performance and safety of its use for detection of colorectal polyps and lack of normal clinical practice modification. The device is a final design version, which has been previously tested in several preclinical studies (including phantom studies, an ex vivo study with human tissues, and an in vivo study with porcine model) and in a pilot study in humans (NCT05477836)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05988645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other MiWEndo Solutions S.L. trials
Trials by the same sponsor.
- NCT05477836 — Feasibility and Safety of MiWEndo-assisted Colonoscopy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05988645 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MiWEndo Solutions S.L.
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05988645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing